Comments
Sun Pharma clocked a net profit of ₹1,391 crore for the three months ended June 30, 2014, compared to a net loss of ₹1,276 crore in the same period last year.
The loss in the first quarter last year was because the company set aside ₹2,517 crore towards settlement on a patent infringement litigation in the US involving the sale of generically similar versions of ‘Protonix’, used to treat gastro-intestinal ulcers and hyperacidity. Sun’s income from operations in the quarter under review stood at ₹3,927 crore, up 13 per cent.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.